

# Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/C766911C67CMEN.html>

Date: February 2018

Pages: 149

Price: US\$ 3,480.00 (Single User License)

ID: C766911C67CMEN

## Abstracts

### Report Summary

Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Commercializing Biomarkers in Therapeutic and Diagnostic Applications industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2013-2017, and development forecast 2018-2023  
Main market players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe, with company and product introduction, position in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market  
Market status and development trend of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by types and applications  
Cost and profit status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, and marketing status  
Market growth drivers and challenges

The report segments the Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications market as:

Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications

Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany  
United Kingdom  
France  
Italy  
Spain  
Benelux  
Russia

Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Consumables  
Services  
Software

Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Oncology  
Cardiology  
Neurology  
Others

Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market: Players Segment Analysis (Company and Product introduction, Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume, Revenue, Price and Gross Margin):

Roche  
Merck  
Merck  
BD  
Abbott  
Genesys Biolabs(20/20GeneSystems)

Affymetrix  
Agendia  
ALMAC  
Arrayit  
Biocartic  
BG Medicine  
KEGG EXPRESSION Database  
Thermo Fisher  
BGI

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

- 1.1 Definition of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in This Report
- 1.2 Commercial Types of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
  - 1.2.1 Consumables
  - 1.2.2 Services
  - 1.2.3 Software
- 1.3 Downstream Application of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
  - 1.3.1 Oncology
  - 1.3.2 Cardiology
  - 1.3.3 Neurology
  - 1.3.4 Others
- 1.4 Development History of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
- 1.5 Market Status and Trend of Commercializing Biomarkers in Therapeutic and Diagnostic Applications 2013-2023
  - 1.5.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status and Trend 2013-2023
  - 1.5.2 Regional Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Status and Trend 2013-2023

### **CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe 2013-2017
- 2.2 Consumption Market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Regions
  - 2.2.1 Consumption Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Regions
  - 2.2.2 Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Regions
- 2.3 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Regions

2.3.1 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Germany 2013-2017

2.3.2 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in United Kingdom 2013-2017

2.3.3 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in France 2013-2017

2.3.4 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Italy 2013-2017

2.3.5 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Spain 2013-2017

2.3.6 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Benelux 2013-2017

2.3.7 Market Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Russia 2013-2017

2.4 Market Development Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe 2018-2023

2.4.1 Market Development Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe 2018-2023

2.4.2 Market Development Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Regions 2018-2023

## **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Types

3.1.2 Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Downstream Industry

4.2 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in Major Countries

4.2.1 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in Germany

4.2.2 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in France

4.2.4 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in Italy

4.2.5 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in Spain

4.2.6 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in Benelux

4.2.7 Demand Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Downstream Industry in Russia

4.3 Market Forecast of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

5.1 Europe Economy Situation and Trend Overview

5.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Downstream Industry Situation and Trend Overview

## **CHAPTER 6 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

6.1 Sales Volume of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Major Players

6.2 Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Europe by Major Players

## 6.3 Basic Information of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Major Players

6.3.1 Headquarters Location and Established Time of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players

6.3.2 Employees and Revenue Level of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players

## 6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

# **CHAPTER 7 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

## 7.1 Roche

7.1.1 Company profile

7.1.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.1.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Roche

## 7.2 Merck

7.2.1 Company profile

7.2.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Merck

## 7.3 Merck

7.3.1 Company profile

7.3.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Merck

## 7.4 BD

7.4.1 Company profile

7.4.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.4.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of BD

## 7.5 Abbott

### 7.5.1 Company profile

### 7.5.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

### 7.5.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Abbott

## 7.6 Genesys Biolabs(20/20GeneSystems)

### 7.6.1 Company profile

### 7.6.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

### 7.6.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Genesys Biolabs(20/20GeneSystems)

## 7.7 Affymetrix

### 7.7.1 Company profile

### 7.7.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

### 7.7.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Affymetrix

## 7.8 Agendia

### 7.8.1 Company profile

### 7.8.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

### 7.8.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Agendia

## 7.9 ALMAC

### 7.9.1 Company profile

### 7.9.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

### 7.9.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of ALMAC

## 7.10 Arrayit

### 7.10.1 Company profile

### 7.10.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

### 7.10.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Arrayit

## 7.11 Biocartic

### 7.11.1 Company profile

### 7.11.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic



## Applications Product

7.11.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Biocartic

## 7.12 BG Medicine

7.12.1 Company profile

7.12.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.12.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of BG Medicine

## 7.13 KEGG EXPRESSION Database

7.13.1 Company profile

7.13.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.13.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of KEGG EXPRESSION Database

## 7.14 Thermo Fisher

7.14.1 Company profile

7.14.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.14.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of Thermo Fisher

## 7.15 BGI

7.15.1 Company profile

7.15.2 Representative Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

7.15.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin of BGI

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

8.1 Industry Chain of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

9.1 Cost Structure Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

9.2 Raw Materials Cost Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

9.3 Labor Cost Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

9.4 Manufacturing Expenses Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

## I would like to order

Product name: Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/C766911C67CMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C766911C67CMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

